OncoMatch/Clinical Trials/NCT07677787
DLL3-Targeted PET/CT in Small Cell Lung Cancer
Is NCT07677787 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for pet/ct.
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: PROGRP expression (≥ 3 times the upper limit of normal)
Serum ProGRP or NSE level ≥ 3 times the upper limit of normal
Required: ENO2 expression (≥ 3 times the upper limit of normal)
Serum ProGRP or NSE level ≥ 3 times the upper limit of normal
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07677787 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require PROGRP?
Yes, PROGRP expression is a required biomarker for enrollment.
Does this trial require ENO2?
Yes, ENO2 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages